Identification and Validation of Methylation-Driven Genes Prognostic Signature for Recurrence of Laryngeal Squamous Cell Carcino

Total Page:16

File Type:pdf, Size:1020Kb

Identification and Validation of Methylation-Driven Genes Prognostic Signature for Recurrence of Laryngeal Squamous Cell Carcino Cui et al. Cancer Cell Int (2020) 20:472 https://doi.org/10.1186/s12935-020-01567-3 Cancer Cell International PRIMARY RESEARCH Open Access Identifcation and validation of methylation-driven genes prognostic signature for recurrence of laryngeal squamous cell carcinoma by integrated bioinformatics analysis Jie Cui3†, Liping Wang2†, Waisheng Zhong4†, Zhen Chen5, Jie Chen4*, Hong Yang3* and Genglong Liu1* Abstract Background: Recurrence remains a major obstacle to long-term survival of laryngeal squamous cell carcinoma (LSCC). We conducted a genome-wide integrated analysis of methylation and the transcriptome to establish methyla- tion-driven genes prognostic signature (MDGPS) to precisely predict recurrence probability and optimize therapeutic strategies for LSCC. Methods: LSCC DNA methylation datasets and RNA sequencing (RNA-seq) dataset were acquired from the Cancer Genome Atlas (TCGA). MethylMix was applied to detect DNA methylation-driven genes (MDGs). By univariate and multivariate Cox regression analyses, fve genes of DNA MDGs was developed a recurrence-free survival (RFS)-related MDGPS. The predictive accuracy and clinical value of the MDGPS were evaluated by receiver operating characteristic (ROC) and decision curve analysis (DCA), and compared with TNM stage system. Additionally, prognostic value of MDGPS was validated by external Gene Expression Omnibus (GEO) database. According to 5 MDGs, the candidate small molecules for LSCC were screen out by the CMap database. To strengthen the bioinformatics analysis results, 30 pairs of clinical samples were evaluated by digoxigenin-labeled chromogenic in situ hybridization (CISH). Results: A total of 88 DNA MDGs were identifed, and fve RFS-related MDGs (LINC01354, CCDC8, PHYHD1, MAGEB2 and ZNF732) were chosen to construct a MDGPS. The MDGPS can efectively divide patients into high-risk and low- risk group, with the area under curve (AUC) of 0.738 (5-year RFS) and AUC of 0.74 (3-year RFS). Stratifcation analysis *Correspondence: [email protected]; [email protected]; lglong3@mail2. sysu.edu.cn †Jie Cui, Liping Wang and Waisheng Zhong contributed equally to this work 1 Department of Pathology, Afliated Cancer Hospital & Institute of Guangzhou Medical University, Guangzhou 510095, Guangdong, P. R. China 3 Department of Head and Neck Surgery, Afliated Cancer Hospital & Institute of Guangzhou Medical University, Guangzhou 510095, Guangdong, P. R. China 4 Department of Head Neck Surgery, Hunan Cancer Hospital and The Afliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha 410000, Hunan, P. R. China Full list of author information is available at the end of the article © The Author(s) 2020. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creat iveco mmons .org/licen ses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creat iveco mmons .org/publi cdoma in/ zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. Cui et al. Cancer Cell Int (2020) 20:472 Page 2 of 19 afrmed that the MDGPS was still a signifcant statistical prognostic model in subsets of patients with diferent clinical variables. Multivariate Cox regression analysis indicated the efcacy of MDGPS appears independent of other clin- icopathological characteristics. In terms of predictive capacity and clinical usefulness, the MDGPS was superior to traditional TNM stage. Additionally, the MDGPS was confrmed in external LSCC cohorts from GEO. CMap matched the 9 most signifcant small molecules as promising therapeutic drugs to reverse the LSCC gene expression. Finally, CISH analysis in 30 LSCC tissues and paired adjacent normal tissues revealed that MAGEB2 has signifcantly higher expres- sion of LSCC compared to adjacent non-neoplastic tissues; LINC01354, CCDC8, PHYHD1, and ZNF732 have signif- cantly lower expression of LSCC compared to adjacent non-neoplastic tissues, which were in line with bioinformatics analysis results. Conclusion: A MDGPS, with fve DNA MDGs, was identifed and validated in LSCC patients by combining transcrip- tome and methylation datasets analysis. Compared TNM stage alone, it generates more accurate estimations of the recurrence prediction and maybe ofer novel research directions and prospects for individualized treatment of patients with LSCC. Keywords: Laryngeal squamous cell carcinoma, DNA methylation-driven genes, Epigenetics, Prediction, Recurrence- free survival Background What’s more, changes in DNA methylation with a high As an aggressively malignant neoplasm, laryngeal squa- level of plasticity allows tumor cells to quickly adapt to mous cell carcinoma (LSCC) is one of the most preva- changes in metabolic restrictions or physiology during lence cancers in head and neck region, and represents the process of tumorigenesis [6, 7]. Hence, it is reason- 85–95% of all laryngeal cancer [1]. According to the able to analyses the DNA methylation pattern in the American Cancer Society, the estimated respective new tumor cells in order to fnd predictors for the recurrence cases and new death are 13 150 and 3 710 annually, with and novel therapeutic targets in LSCC patients. incidence and mortality rates of 4.0 and 1.1 per 100 000, Te availability of high throughput genomic assays respectively [2]. Current multimode treatments, includ- such as RNA-seq and DNA methylation-seq have opened ing surgery, radiotherapy, chemotherapy, targeted ther- the possibility for a comprehensive characterization of all apy and so on, are applied to cure LSCC patients [3]. molecular alterations of cancers, leading to the discovery Tough treatments have improved during the past dec- of new biomarkers of clinical and therapeutic value [8]. In ades, long-term survival is hampered as more than 40% present study, we performed a genome-wide integrated of LSCC patients experience disease recurrence approxi- analysis of methylation and the transcriptome to charac- mately at 5 years after radical treatment [4]. terize the crosstalk between DNA methylation and RNA Hence, identifying accurate predictive models and reli- regulation for patients with LSCC in Te Cancer Genome able biomarkers to screen out which subset of patients Atlas (TCGA) database. We identify methylation-driven with LSCC is apt to develop recurrence is urgently genes (MDGs), and then developed a methylation-driven needed, which help to optimize therapeutic strategies genes prognostic signature (MDGPS) capable of predict- and exploit valuable molecular targeted therapy in LSCC ing the recurrence-free survival (RFS), and further screen patients. correlated small molecule target drugs. Te proposed LSCC is a heterogeneous disease in terms of therapeu- MDGPS was validated in external datasets from the GEO tic response and clinical prognosis. To a certain extent, database. In additional, we assessed the predictive ability clinical heterogeneity can be related to distinct molecu- and clinical application of the MDGPS and compared it lar subtypes by gene expression pattern [5].RNA expres- to the TNM stage. sion profles usually exhibits relative stochastic and rapid variations, which can be directly related to important Materials and methods pathways in malignant cells. DNA methylation, serves Sample selection and data processing as a major epigenetic modifcation that is involved in the We downloaded DNA methylation (111 LSCC sam- transcriptional regulation of genes and maintains the sta- ples and 12 normal samples), RNA-sequencing profles bility of the genome, is less variable and semi-stable, but (117 LSCC samples and 16 normal samples) and clini- show large variations linked to the activity of cellular pro- cal information data (Additional fle 1: Material S1) of cesses. Terefore, the combination of transcriptome and LSCC patients from TCGA (https ://gdc.cance r.gov/), epigenetic status would be helpful to identify new mark- which recorded before February 14, 2020. Excluding the ers and improve the accuracy of recurrence prediction. unavailability of DNA methylation or gene transcriptome Cui et al. Cancer Cell Int (2020) 20:472 Page 3 of 19 datasets or RFS time < 1 month, as a result, a total of methylation (DM) value where gene with a positive DM 81 LSCC patients were enrolled in this analysis. Te value of signifes hypermethylation and gene with a nega- GSE27020 microarray dataset (https ://www.ncbi.nlm. tive DM value signifes hypomethylation can be applied nih.gov/geo/query /acc.cgi?acc=GSE27 020) comprises in subsequent analysis. 109 LSCC specimens with gene expression profles and the associated clinical characteristics (Additional fle 2: Functional enrichment and pathway analysis Material S2).GSE25727 microarray dataset (https :// of methylation‑driven genes www.ncbi.nlm.nih.gov/geo/query /acc.cgi?acc=GSE25 Gene
Recommended publications
  • Clinical Utility Gene Card For: 3-M Syndrome – Update 2013
    European Journal of Human Genetics (2014) 22, doi:10.1038/ejhg.2013.156 & 2014 Macmillan Publishers Limited All rights reserved 1018-4813/14 www.nature.com/ejhg CLINICAL UTILITY GENE CARD UPDATE Clinical utility gene card for: 3-M syndrome – Update 2013 Muriel Holder-Espinasse*,1, Melita Irving1 and Vale´rie Cormier-Daire2 European Journal of Human Genetics (2014) 22, doi:10.1038/ejhg.2013.156; published online 31 July 2013 Update to: European Journal of Human Genetics (2011) 19, doi:10.1038/ejhg.2011.32; published online 2 March 2011 1. DISEASE CHARACTERISTICS nonsense and missense mutations c.4333C4T (p.Arg1445*) and 1.1 Name of the disease (synonyms) c.4391A4C (p.His1464Pro), respectively, render CUL7 deficient 3-M syndrome (gloomy face syndrome, dolichospondylic dysplasia). in recruiting ROC1, leading to impaired ubiquitination. OBSL1: microsatellites analysis of the locus (2q35-36.1) in con- 1.2 OMIM# of the disease sanguineous families. OBSL1: microsatellites analysis of the locus 273750. (2q35-36.1) in consanguineous families. Mutations induce non- sense mediated decay. Knockdown of OBSL1 in HEK293 cells 1.3 Name of the analysed genes or DNA/chromosome segments shows the role of this gene in the maintenance of normal levels of CUL7, OBSL1 and CCDC8.1–5 CUL7. Abnormal IGFBP2 andIGFBP5 mRNA levels in two patients with OBSL1 mutations, suggesting that OBSL1 modulates the 1.4 OMIM# of the gene(s) expression of IGFBP proteins. CCDC8: microsatellites analysis 609577 (CUL7), 610991 (OBSL1) and 614145 (CCDC8). at the locus (19q13.2-q13.32). CCDC8, 1-BP DUP, 612G and CCDC8, 1-BP.
    [Show full text]
  • NIH Public Access Author Manuscript Mol Cell
    NIH Public Access Author Manuscript Mol Cell. Author manuscript; available in PMC 2015 June 05. NIH-PA Author ManuscriptPublished NIH-PA Author Manuscript in final edited NIH-PA Author Manuscript form as: Mol Cell. 2014 June 5; 54(5): 791–804. doi:10.1016/j.molcel.2014.03.047. The 3M complex maintains microtubule and genome integrity Jun Yan1, Feng Yan1, Zhijun Li1, Becky Sinnott4, Kathryn M. Cappell4,7, Yanbao Yu2, Jinyao Mo5, Joseph A. Duncan1,5, Xian Chen2, Valerie Cormier-Daire6, Angelique W. Whitehurst4,8, and Yue Xiong1,2,3,* 1Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599-7295, USA. 2Department of Biochemistry and Biophysics, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599-7295, USA. 3Program in Molecular Biology and Biotechnology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599-7295, USA. 4Department of Pharmacology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599-7295, USA. 5Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599-7295, USA. 6University Paris Descartes, Department of Genetics and INSERM U781, Hospital Necker Enfants-Malades, Paris, France SUMMARY CUL7, OBSL1, and CCDC8 genes are mutated in a mutually exclusive manner in 3M and other growth retardation syndromes. The mechanism underlying the function of the three 3M genes in development is not known. We found that OBSL1 and CCDC8 form a complex with CUL7 and regulate the level and centrosomal localization of CUL7, respectively. CUL7 depletion results in altered microtubule dynamics, prometaphase arrest, tetraploidy and mitotic cell death.
    [Show full text]
  • Why It Is Difficult to Distinguish the Silver-Russell
    Why it is dicult to distinguish the Silver-Russell syndrome (SRS) and 3M syndrome in clinical practice Beibei Zhang Department of Endocrinology, Genetics, Metabolism, Beijing Children’s Hospital, Capital Medical University, National Center for Children’s Health, Beijing 100045, China Chunxiu Gong ( [email protected] ) Department of Endocrinology, Genetics, Metabolism, Beijing Children’s Hospital, Capital Medical University, National Center for Children’s Health, Beijing 100045, China Research Keywords: Silver-Russell syndrome, 3M syndrome, NH-CSS, Phenotype Posted Date: April 15th, 2020 DOI: https://doi.org/10.21203/rs.3.rs-22088/v1 License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License Page 1/10 Abstract Background: To analyze why 3M syndrome can be regarded as a SRS-like syndrome by examining the patients with 3M syndrome and research the connection between 3M syndrome and SRS. Methods: The term “3M syndrome” was retrieved by Web of Science and the 3M patients were screened by NH-CSS to determine whether it was consist with the diagnosis of clinical SRS, and to analyze the relationship between the two diseases by exploring literature. Results: Among patients with 3M syndrome, 60/70 (83%) were in accordance with clinical SRS, and the coincidence rates of CUL7, OBSL1, CCDC8 gene mutations were: 30 (42%), 17 (24%) and 4 (6%) respectively; The phenotypes of 3M syndrome conrmed as clinical SRS were SGA (90%), short stature (100%), forehead protruding (100%), relative macrocephaly (100%), feeding diculties/low BMI (33%), body asymmetry (0); Skeletal abnormalities and pathogenesis were previously considered as the key points of differentiation also were overlaps between two diseases; Symptomatic treatment and GH- treatment were carried out.
    [Show full text]
  • Identification of DNA Methylation-Driven Genes in Esophageal Squamous Cell Carcinoma: a Study Based on the Cancer Genome Atlas
    Lu et al. Cancer Cell Int (2019) 19:52 https://doi.org/10.1186/s12935-019-0770-9 Cancer Cell International PRIMARY RESEARCH Open Access Identifcation of DNA methylation-driven genes in esophageal squamous cell carcinoma: a study based on The Cancer Genome Atlas Tong Lu1, Di Chen2, Yuanyong Wang1, Xiao Sun1, Shicheng Li1, Shuncheng Miao1, Yang Wo1, Yanting Dong1, Xiaoliang Leng1, Wenxing Du1 and Wenjie Jiao1* Abstract Background: Aberrant DNA methylations are signifcantly associated with esophageal squamous cell carcinoma (ESCC). In this study, we aimed to investigate the DNA methylation-driven genes in ESCC by integrative bioinformatics analysis. Methods: Data of DNA methylation and transcriptome profling were downloaded from TCGA database. DNA methylation-driven genes were obtained by methylmix R package. David database and ConsensusPathDB were used to perform gene ontology (GO) analysis and pathway analysis, respectively. Survival R package was used to analyze overall survival analysis of methylation-driven genes. Results: Totally 26 DNA methylation-driven genes were identifed by the methylmix, which were enriched in molecu- lar function of DNA binding and transcription factor activity. Then, ABCD1, SLC5A10, SPIN3, ZNF69, and ZNF608 were recognized as signifcant independent prognostic biomarkers from 26 methylation-driven genes. Additionally, a fur- ther integrative survival analysis, which combined methylation and gene expression data, was identifed that ABCD1, CCDC8, FBXO17 were signifcantly associated with patients’ survival. Also, multiple aberrant methylation sites were found to be correlated with gene expression. Conclusion: In summary, we studied the DNA methylation-driven genes in ESCC by bioinformatics analysis, ofering better understand of molecular mechanisms of ESCC and providing potential biomarkers precision treatment and prognosis detection.
    [Show full text]
  • The GALNT9, BNC1 and CCDC8 Genes Are Frequently Epigenetically Dysregulated in Breast Tumours That Metastasise to the Brain Rajendra P
    Pangeni et al. Clinical Epigenetics (2015) 7:57 DOI 10.1186/s13148-015-0089-x RESEARCH Open Access The GALNT9, BNC1 and CCDC8 genes are frequently epigenetically dysregulated in breast tumours that metastasise to the brain Rajendra P. Pangeni1, Prasanna Channathodiyil1, David S. Huen2, Lawrence W. Eagles1, Balraj K. Johal2, Dawar Pasha2, Natasa Hadjistephanou2, Oliver Nevell2, Claire L. Davies2, Ayobami I. Adewumi2, Hamida Khanom2, Ikroop S. Samra2, Vanessa C. Buzatto2, Preethi Chandrasekaran2, Thoraia Shinawi3, Timothy P. Dawson4, Katherine M. Ashton4, Charles Davis4, Andrew R. Brodbelt5, Michael D. Jenkinson5, Ivan Bièche6, Farida Latif3, John L. Darling1, Tracy J. Warr1 and Mark R. Morris1,2,3* Abstract Background: Tumour metastasis to the brain is a common and deadly development in certain cancers; 18–30 % of breast tumours metastasise to the brain. The contribution that gene silencing through epigenetic mechanisms plays in these metastatic tumours is not well understood. Results: We have carried out a bioinformatic screen of genome-wide breast tumour methylation data available at The Cancer Genome Atlas (TCGA) and a broad literature review to identify candidate genes that may contribute to breast to brain metastasis (BBM). This analysis identified 82 candidates. We investigated the methylation status of these genes using Combined Bisulfite and Restriction Analysis (CoBRA) and identified 21 genes frequently methylated in BBM. We have identified three genes, GALNT9, CCDC8 and BNC1, that were frequently methylated (55, 73 and 71 %, respectively) and silenced in BBM and infrequently methylated in primary breast tumours. CCDC8 was commonly methylated in brain metastases and their associated primary tumours whereas GALNT9 and BNC1 were methylated and silenced only in brain metastases, but not in the associated primary breast tumours from individual patients.
    [Show full text]
  • Chamber-Enriched Gene Expression Profiles in Failing Human Hearts with Reduced Ejection Fraction
    www.nature.com/scientificreports OPEN Chamber‑enriched gene expression profles in failing human hearts with reduced ejection fraction Xin Luo1, Jun Yin1, Denise Dwyer2, Tracy Yamawaki1, Hong Zhou1, Hongfei Ge3, Chun‑Ya Han2, Artem Shkumatov4, Karen Snyder5, Brandon Ason3, Chi‑Ming Li1, Oliver Homann1 & Marina Stolina2* Heart failure with reduced ejection fraction (HFrEF) constitutes 50% of HF hospitalizations and is characterized by high rates of mortality. To explore the underlying mechanisms of HFrEF etiology and progression, we studied the molecular and cellular diferences in four chambers of non‑failing (NF, n = 10) and HFrEF (n = 12) human hearts. We identifed 333 genes enriched within NF heart subregions and often associated with cardiovascular disease GWAS variants. Expression analysis of HFrEF tissues revealed extensive disease‑associated transcriptional and signaling alterations in left atrium (LA) and left ventricle (LV). Common left heart HFrEF pathologies included mitochondrial dysfunction, cardiac hypertrophy and fbrosis. Oxidative stress and cardiac necrosis pathways were prominent within LV, whereas TGF‑beta signaling was evident within LA. Cell type composition was estimated by deconvolution and revealed that HFrEF samples had smaller percentage of cardiomyocytes within the left heart, higher representation of fbroblasts within LA and perivascular cells within the left heart relative to NF samples. We identifed essential modules associated with HFrEF pathology and linked transcriptome discoveries with human genetics fndings. This study contributes to a growing body of knowledge describing chamber‑specifc transcriptomics and revealed genes and pathways that are associated with heart failure pathophysiology, which may aid in therapeutic target discovery. By physiological function, the human heart is a muscular pump that circulates blood, perfusing tissues through- out the body.
    [Show full text]
  • Two Siblings with a Mutation in CCDC8 Presenting with Mild Short Stature: a Mild Case of 3-M Syndrome
    Two Siblings with a Mutation in CCDC8 Presenting with Mild Short Stature: A Mild Case of 3-M Syndrome Lihong Liao1*, Hoong-Wei Gan2*, Vivian Hwa1, Mehul Dattani2, Andrew Dauber1 1. Cincinnati Center for Growth Disorders, Division of Endocrinology, Cincinnati Children’s Hospital Medical Center 2. Section of Genetics and Epigenetics in Health and Disease, Genetics and Genomic Medicine Programme, University College London Great Ormond Street Institute of Child Health London, UK *These authors contributed equally to this work. Dr. Dauber is a member of both ESPE and PES. Short Title: Mutation in CCDC8 Causing Mild Short Stature Corresponding Author: Andrew Dauber Division of Endocrinology, Cincinnati Children’s Hospital Medical Center 3333 Burnet Ave., MLC 7012 Cincinnati, OH 45229-3039 USA Phone: 513-803-7027 Fax: 513-803-1174 Email: [email protected] Key words: 3M syndrome; CCDC8; whole exome sequencing; short stature The authors have no conflicts of interest to declare. Established Facts: 3-M syndrome is a growth disorder presenting with severe pre- and post-natal growth retardation and is caused by mutations in three genes (CUL7, 1 OBSL1, and CCDC8). Novel Insights: We describe two siblings with quite mild short stature who carry a homozygous pathogenic mutation in CCDC8causative of 3-M syndrome. This is the mildest case of 3-M syndrome reported to date and demonstrates the utility of genomic screening in children with undiagnosed growth disorders, especially from consanguineous families. Abstract Background: Short stature can be caused by mutations in a multitude of different genes. 3-M syndrome is a rare growth disorder marked by severe pre- and post-natal growth retardation along with subtle dysmorphic features.
    [Show full text]
  • Impaired Plasma Membrane Localization of Ubiquitin Ligase Complex Underlies 3-M Syndrome Development
    Impaired plasma membrane localization of ubiquitin ligase complex underlies 3-M syndrome development Pu Wang, … , Scott E. Parnell, Yue Xiong J Clin Invest. 2019. https://doi.org/10.1172/JCI129107. Research In-Press Preview Development Genetics Graphical abstract Find the latest version: https://jci.me/129107/pdf Impaired plasma membrane localization of ubiquitin ligase complex underlies 3-M syndrome development Pu Wang1, Feng Yan1, Zhijun Li1, Yanbao Yu2, Scott E. Parnell3,4 and Yue Xiong1,5,6* 1Lineberger Comprehensive Cancer Center, 3Bowles Center for Alcohol Studies, 4Department of Cell Biology and Physiology, 5Department of Biochemistry and Biophysics, 6Integrative Program for Biological and Genome Sciences, University of North Carolina at Chapel Hill, NC 27599. 2J. Craig Venter Institute, 9605 Medical Center Drive, Rockville, MD 20850 *Correspondence: Yue Xiong, Ph.D. E-mail: [email protected] Tel: (919)-962-2142 / Fax: (919)-966-8799 22-012 Lineberger Building, CB# 7295 University of North Carolina at Chapel Hill Chapel Hill, NC 27599-7295 1 ABSTRACT 3-M primordial dwarfism is an inherited disease characterized by severe pre- and postnatal growth retardation and by mutually exclusive mutations in three genes, CUL7, OBSL1, and CCDC8. The mechanism underlying 3-M dwarfism is not clear. We showed here that CCDC8, derived from a retrotransposon Gag protein in placental mammals, exclusively localized on the plasma membrane and was phosphorylated by CK2 and GSK3. Phosphorylation of CCDC8 resulted in its binding first with OBSL1, and then CUL7, leading to the membrane assembly of the 3-M E3 ubiquitin ligase complex. We identified LL5β, a plasma membrane protein that regulates cell migration, as a substrate of 3-M ligase.
    [Show full text]
  • Impaired Plasma Membrane Localization of Ubiquitin Ligase Complex Underlies 3-M Syndrome Development
    The Journal of Clinical Investigation RESEARCH ARTICLE Impaired plasma membrane localization of ubiquitin ligase complex underlies 3-M syndrome development Pu Wang,1 Feng Yan,1 Zhijun Li,1 Yanbao Yu,2 Scott E. Parnell,3,4 and Yue Xiong1,5,6 1Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, North Carolina, USA. 2J. Craig Venter Institute, Rockville, Maryland, USA. 3Bowles Center for Alcohol Studies, 4Department of Cell Biology and Physiology, 5Department of Biochemistry and Biophysics, and 6Integrative Program for Biological and Genome Sciences, University of North Carolina at Chapel Hill, North Carolina, USA. 3-M primordial dwarfism is an inherited disease characterized by severe pre- and postnatal growth retardation and by mutually exclusive mutations in 3 genes, CUL7, OBSL1, and CCDC8. The mechanism underlying 3-M dwarfism is not clear. We showed here that CCDC8, derived from a retrotransposon Gag protein in placental mammals, exclusively localized on the plasma membrane and was phosphorylated by CK2 and GSK3. Phosphorylation of CCDC8 resulted in its binding first with OBSL1, and then CUL7, leading to the membrane assembly of the 3-M E3 ubiquitin ligase complex. We identified LL5β, a plasma membrane protein that regulates cell migration, as a substrate of 3-M ligase. Wnt inhibition of CCDC8 phosphorylation or patient-derived mutations in 3-M genes disrupted membrane localization of the 3-M complex and accumulated LL5β. Deletion of Ccdc8 in mice impaired trophoblast migration and placental development, resulting in intrauterine growth restriction and perinatal lethality. These results identified a mechanism regulating cell migration and placental development that underlies the development of 3-M dwarfism.
    [Show full text]
  • Rare Cnvs Provide Novel Insights Into the Molecular Basis of GH and IGF-1 Insensitivity
    6 183 E Cottrell and others CNVs in GH and IGF-1 183:6 581–595 Clinical Study insensitivity Rare CNVs provide novel insights into the molecular basis of GH and IGF-1 insensitivity Emily Cottrell1, Claudia P Cabrera2,3, Miho Ishida4, Sumana Chatterjee1, James Greening5, Neil Wright6, Artur Bossowski7, Leo Dunkel1, Asma Deeb8, Iman Al Basiri9, Stephen J Rose10, Avril Mason11, Susan Bint12, Joo Wook Ahn13, Vivian Hwa14, Louise A Metherell1, Gudrun E Moore4 and Helen L Storr1 1Centre for Endocrinology, William Harvey Research Institute, Barts and the London School of Medicine & Dentistry, Queen Mary University of London, London, UK, 2Centre for Translational Bioinformatics, Queen Mary University of London, London, UK, 3NIHR Barts Cardiovascular Biomedical Research Centre, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK, 4University College London, Great Ormond Street Institute of Child Health, London, UK, 5University Hospitals of Leicester NHS Trust, Leicester, UK, 6The University of Sheffield Faculty of Medicine, Dentistry and Health, Sheffield, UK, 7Department of Pediatrics, Endocrinology and Diabetes with a Cardiology Unit, Medical University of Bialystok, Bialystok, Poland, 8Paediatric Endocrinology Department, Mafraq Hospital, Abu Dhabi, United Arab Emirates, 9Mubarak Al-kabeer Hospital, Jabriya, Kuwait, 10University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK, 11Royal Correspondence Hospital for Children, Glasgow, UK, 12Viapath, Guy’s Hospital, London, UK, 13Addenbrookes Hospital, Cambridge, UK, should be addressed and 14Cincinnati Center for Growth Disorders, Division of Endocrinology, Cincinnati Children’s Hospital Medical to H L Storr Center, Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA Email [email protected] Abstract Objective: Copy number variation (CNV) has been associated with idiopathic short stature, small for gestational age and Silver-Russell syndrome (SRS).
    [Show full text]
  • Differential Gene Expression in the Peripheral Zone Compared to the Transition Zone of the Human Prostate Gland
    Prostate Cancer and Prostatic Diseases (2008) 11, 173–180 & 2008 Nature Publishing Group All rights reserved 1365-7852/08 $30.00 www.nature.com/pcan ORIGINAL ARTICLE Differential gene expression in the peripheral zone compared to the transition zone of the human prostate gland EE Noel1,4, N Ragavan2,3,4, MJ Walsh2, SY James1, SS Matanhelia3, CM Nicholson3, Y-J Lu1 and FL Martin2 1Medical Oncology Centre, Institute of Cancer, Barts and London School of Medicine and Dentistry Queen Mary, University of London, London, UK; 2Biomedical Sciences Unit, Department of Biological Sciences, Lancaster University, Lancaster, UK and 3Lancashire Teaching Hospitals NHS Trust, Preston, UK Gene expression profiles may lend insight into whether prostate adenocarcinoma (CaP) predominantly occurs in the peripheral zone (PZ) compared to the transition zone (TZ). From human prostates, tissue sets consisting of PZ and TZ were isolated to investigate whether there is a differential level of gene expression between these two regions of this gland. Gene expression profiling using Affymetrix Human Genome U133 plus 2.0 arrays coupled with quantitative real- time reverse transcriptase-PCR was employed. Genes associated with neurogenesis, signal transduction, embryo implantation and cell adhesion were found to be expressed at a higher level in the PZ. Those overexpressed in the TZ were associated with neurogenesis development, signal transduction, cell motility and development. Whether such differential gene expression profiles may identify molecular mechanisms responsible
    [Show full text]
  • Ankyrin Repeats in Context with Human Population Variation
    bioRxiv preprint doi: https://doi.org/10.1101/2021.05.28.445974; this version posted May 30, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license. 1 Ankyrin repeats in context with 2 human population variation 3 Javier S. Utgés1,2, Maxim I. Tsenkov1, Noah J. M. Dietrich1, 4 Stuart A. MacGowan1 and Geoffrey J. Barton1* 5 1Division of Computational Biology, School of Life Sciences, University 6 of Dundee, Scotland, UK 7 2Universitat Pompeu Fabra (UPF), Barcelona, Spain 8 9 *Correspondence to: [email protected] 10 1 bioRxiv preprint doi: https://doi.org/10.1101/2021.05.28.445974; this version posted May 30, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license. 11 Abstract 12 Ankyrin protein repeats bind to a wide range of substrates and are one of the most common protein 13 motifs in nature. Here, we collate a high-quality alignment of 7,407 ankyrin repeats and examine 14 for the first time, the distribution of human population variants from large-scale sequencing of 15 healthy individuals across this family. Population variants are not randomly distributed across the 16 genome but are constrained by gene essentiality and function. Accordingly, we interpret the 17 population variants in context with evolutionary constraint and structural features including 18 secondary structure, accessibility and protein-protein interactions across 383 three-dimensional 19 structures of ankyrin repeats.
    [Show full text]